Abstract
Nearly 15 years have passed since Pedro and Josep Brugada introduced the syndrome of ST-segment elevation and right bundle branch block (RBBB) associated with a high incidence of ventricular tachycardia/ventricular fibrillation (VT/VF) as a new clinical entity.1 Over 16 years have transpired since the introduction of the concept of phase 2 reentry (induced by sodium channel block), the mechanism believed to underlie the development of arrhythmogenesis in this clinical syndrome.2,3 Thus, the entity, which in 1996 came to be known as the Brugada syndrome,4,5 evolved in the experimental laboratory and in the clinic along parallel but separate tracks until the late 1990s.6
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Brugada P, Brugada J Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocar-diographic syndrome: A multicenter report. J Am Coll Cardiol 1992;20:1391–1396.
Krishnan SC, Antzelevitch C. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. CircRes 1991;69:277–291.
Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 1993;87:562–572.
Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 1996;93:372–379.
Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome.J Am Coll Cardiol 1996;27:1061–1070.
Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:513–516.
Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. Eur Heart J 2002;23:1648–1654.
Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, Priori SG, Towbin JA. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. Circulation 2002;106:2514–2519.
Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada Syndrome. Report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;1 11:659–6
Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze-Bahr E, Tan H, Wilde A. Brugada syndrome: Report of the second consensus conference. Heart Rhythm 2005;2:429–440.
Brugada P, Brugada J, Brugada R. Arrhythmia induction by antiarrhythmic drugs. Pacing Clin Electrophysiol 2000;23:291–292.
Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510–515.
Antzelevitch C, Brugada R. Fever and the Brugada syndrome. Pacing Clin Electrophysiol 2002;25:1537–1539.
Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1320–1329.
Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Brignole M, Giordano U, Giovannini T, Menozzi C, Bloise R, Crotti L, Terreni L, Schwartz PJ. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000;102:2509–2515.
Wolpert C., Echternach C, Veltmann C, Antzelevitch C, Thomas GP, Sphel S, Streitner F, Kuschyk J, Schimpf R, Haase KK, Borggrefe M. Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm 2005;2:254–260.
Hong K, Brugada J, Oliva A, Berruezo-Sanchez A, Potenza D, Pollevick GD, Guerchicoff A, Matsuo K, Burashnikov E, Dumaine R, Towbin JA, Nesterenko VV, Brugada P, Antzelevitch C, Brugada R. Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation 2004;110:3023–3027.
Itoh H, Shimizu M, Takata S, Mabuchi H, Imoto K. A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol 2005;16:486–493.
Kalla H, Yan GX, Marinchak R. Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: A Brugada syndrome variant? J Cardiovasc Electrophysiol 2000;11:95–98.
Ogawa M, Kumagai K, Yamanouchi Y, Saku K. Spontaneous onset of ventricular fibrillation in Brugada syndrome with J wave and ST-segment elevation in the inferior leads. Heart Rhythm 2005;2:97–99.
Horigome H, Shigeta O, Kuga K, Isobe T, Sakakibara Y, Yamaguchi I, Matsui A. Ventricular fibrillation during anesthesia in association with J waves in the left precordial leads in a child with coarctation of the aorta. J Electrocardiol 2003;36:339–343.
Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: Clinical implication of eightyseven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 2000;11:396–404.
Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. Eur Heart J 2001;22:2290–2296.
Shin SC, Ryu S, Lee JH, Chang BJ, Shin JK, Kim HS, Heo JH, Yang DH, Park HS, Cho Y, Chae SC, Jun JE, Park WH. Prevalence of the Brugada-type ECG recorded from higher intercostal spaces in healthy Korean males. Circulation J 2005;69:1064–1067.
Alings M, Wilde A. “Brugada” syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999;99:666–673.
Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, Van Langen IM, Tan-Sindhunata G, Bink-Boelkens MT, Der Hout AH, Mannens MM, Wilde AA. A single Na(+) channel mutation causing both long-QT and Brugada syndromes. Circ Res 1999;85:1206–1213.
Pitzalis MV, Anaclerio M, Iacoviello M, Forleo C, Guida P, Troccoli R, Massari F, Mastropasqua F, Sorrentino S, Manghisi A, Rizzon P. QT-interval prolongation in right precordial leads: An additional electrocardiographic hallmark of Brugada syndrome. J Am Coll Cardiol 2003;42:1632–1637.
Castro HJ, Antzelevitch C, Tornes BF, Dorantes SM, Dorticos BF, Zayas MR, Quinones Perez MA, Fayad RY. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006;47:1828–1834.
Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA. Genotype-phenotype relationship in Brugada syndrome: Electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol 2002;40:350–356.
Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M, Toyoshima Y, Hosoda S. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95:2277–2285.
Proclemer A, Facchin D, Feruglio GA, Nucifora R. Recurrent ventricular fibrillation, right bundle-branch block and persistent ST-segment elevation in V1-V3: A new arrhythmia syndrome? A clinical case report (see comments). GItal Cardiol 1993;23:1211–1218.
Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, Kobori A, Ninomiya T, Yoshida H, Takano M, Makita N, Yanagisawa F, Higashi Y, Takeyama Y, Kita T, Horie M. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:2100–2106.
Scornik FS, Desai M, Brugada R, Guerchicoff A, Pollevick GD, Antzelevitch C, Perez GJ. Functional expression of “cardiac-type” Na(v)1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm 2006;3:842–850.
Shimada M, Miyazaki T, Miyoshi S, Soejima K, Hori S, Mitamura H, Ogawa S. Sustained monomorphic ventricular tachycardia in a patient with Brugada syndrome. Jpn Circ J 1996;60:364–370.
Pinar BE, Garcia-Alberola A, Martinez SJ, Sanchez Munoz JJ, Valdes CM. Spontaneous sustained monomorphic ventricular tachycardia after administration of ajmaline in a patient with Brugada syndrome [see comments]. Pacing Clin Electrophysiol 2000;23:407–409.
Dinckal MH, Davutoglu V, Akdemir I, Soydinc S, Kirilmaz A, Aksoy M. Incessant monomorphic ventricular tachycardia during febrile illness in a patient with Brugada syndrome: Fatal electrical storm. Europace 2003;5:257–261.
Mok NS, Chan NY. Brugada syndrome presenting with sustained monomorphic ventricular tachycardia. Int J Cardiol 2004;97:307–309.
Probst V, Evain S, Gournay V, Marie A, Schott JJ, Boisseau P, Le MH. Monomorphic ventricular tachycardia due to Brugada syndrome successfully treated by hydroquinidine therapy in a 3-year-old child. J Cardiovasc Electrophysiol 2006;17:97–100.
Sastry BK, Narasimhan C, Soma RB. Brugada syndrome with monomorphic ventricular tachycardia in a one-year-old child. Indian Heart J 2001;53:203–205.
Remme CA, Wever EFD, Wilde AAM, Derksen R, Hauer RNW. Diagnosis and long-term follow-up of Brugada syndrome in patients with idiopathic ventricular fibrillation. Eur Heart J 2001;22:400–409.
Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V(1) to V(3). Circulation 2002;105:73–
Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, Ronchetti E, Faggiano G, Nastoli J. Natural history of Brugada syndrome: Insights for risk stratification and management. Circulation 2002;105:1342–1347.
Brugada P, Brugada R, Brugada J. Patients with an asymptomatic Brugada electrocardiogram should undergo pharmacological and electrophysical testing. Circulation 2005;1 12:279–285.
Priori SG, Napolitano C. Management of patients with Brugada syndrome should not be based on programmed electrical stimulation. Circulation 2005;1 12:285–2
Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, Wichter T, Boisseau P, Heinecke A, Breithardt G, Borggrefe M, LeMarec H, Bocker D, Wilde AA. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circula tion 2005;111:257–263.
Atarashi H, Ogawa S, for The Idiopathic Ventricular Fibrillation Investigators. New ECG criteria for high-risk Brugada syndrome. Circ J 2003;67:8–10.
Morita H, Takenaka-Morita S, Fukushima-Kusano K, Kobayashi M, Nagase S, Kakishita M, Nakamura K, Emori T, Matsubara H, Ohe T. Risk stratification for asymptomatic patients with Brugada syndrome. Circ J 2003;67:312–316.
Viskin S. Inducible ventricular fibrillation in the Brugada syndrome: Diagnostic and prognostic implications. J Cardiovasc Electrophysiol 2003;14:458–460.
Brugada J, Brugada R, Brugada P. Right bundlebranch block and ST-segment elevation in leads V1 through V3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457–460.
Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol 2002;39:1799–1805.
Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003;108:3092–3096.
Eckardt L, Kirchhof P, Johna R, Haverkamp W, Breithardt G, Borggrefe M. Wolff-Parkinson-White syndrome associated with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1423–1424.
Carlsson J, Erdogan A, Schulte B, Neuzner J, Pitschner HF. Possible role of epicardial left ventricular programmed stimulation in Brugada syndrome. Pacing Clin Electrophysiol 2001;24:247–249.
Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: A meta-analysis. J Cardiovasc Electrophysiol 2006;17:577–583.
Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O’Brien RE, Schultze-Bahr E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998;392:293–296.
Grant AO, Carboni MP, Neplioueva V, Starmer CF, Memmi M, Napolitano C, Priori SG. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 2002;1 10:1201–1209.
Antzelevitch C, Brugada P, Brugada J, Brugada R. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura, 2005.
Balser JR. The cardiac sodium channel: Gating function and molecular pharmacology. J Mol Cell Cardiol 2001;33:599–613.
Schulze-Bahr E, Eckardt L, Breithardt G, Seidl K, Wichter T, Wolpert C, Borggrefe M, Haverkamp W. Sodium channel gene (SCN5A) mutations in 44 index patients with Brugada syndrome: Different incidences in familial and sporadic disease. Hum Mutat 2003;21:651–652.
Bezzina CR, Wilde AA, Roden DM. The molecular genetics of arrhythmias. Cardiovasc Res 2005;67:343–346.
Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA. Genetic control of sodium channel function. Cardiovasc Res 2003;57:961–973.
Antzelevitch C, Brugada P, Brugada J, Brugada R. The Brugada syndrome. From cell to bedside. Curr Probl Cardiol 2005;30:9–54.
Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko VV, Nesterenko DV, Brugada J, Brugada R, Antzelevitch C. Ionic mechanisms responsible for the electrocardiographic pheno-type of the Brugada syndrome are temperature dependent. Circ Res 1999;85:803–809.
Saura D, Garcia-Alberola A, Carrillo P, Pascual D, Martinez-Sanchez J, Valdes M. Brugada-like electrocardiographic pattern induced by fever. Pacing Clin Electrophysiol 2002;25:856–859.
Porres JM, Brugada J, Urbistondo V, Garcia F, Reviejo K, Marco P. Fever unmasking the Brugada syndrome. Pacing Clin Electrophysiol 2002;25:1646–1648.
Mok NS, Priori SG, Napolitano C, Chan NY, Chahine M, Baroudi G. A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia. J Cardiovasc Electrophysiol 2003;14:407–4
Ortega-Carnicer J, Benezet J, Ceres F. Feverinduced ST-segment elevation and T-wave alternans in a patient with Brugada syndrome. Resuscitation 2003;57:315–317.
Patruno N, Pontillo D, Achilli A, Ruggeri G, Critelli G. Electrocardiographic pattern of Brugada syndrome disclosed by a febrile illness: Clinical and therapeutic implications. Europace 2003;5:251–255.
Peng J, Cui YK, Yuan FH, Yi SD, Chen ZM, Meng SR. [Fever and Brugada syndrome: Report of 21 cases.]. Di Yi Jun Yi Da Xue Xue Bao 2005;25:432–434.
Dulu A, Pastores SM, McAleer E, Voigt L, Halpern NA. Brugada electrocardiographic pattern in a postoperative patient. Crit Care Med 2005;33:1634–1637.
Aramaki K, Okumura H, Shimizu M. Chest pain and ST elevation associated with fever in patients with asymptomatic Brugada syndrome. Fever and chest pain in Brugada syndrome. Int J Cardiol 2005;103:338–3
Hong K, Guerchicoff A, Pollevick GD, Oliva A, Dumaine R, de Zutter M, Burashnikov E, Wu YS, Brugada J, Brugada P, Brugada R. Cryptic 5’ splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol 2005;38:555–560.
Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, Kamakura S, Roden DM, Wilde AA. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006;113:338–344.
Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, Angelilli A, Villanueva F, McNamara DM, London B. Clinical and molecular heterogeneity in the Brugada syndrome. A novel gene locus on chromosome 3. Circulation 2002;105:707–7
London B, Sanyal S, Michalec M, Pfahnl AE, Shang LL, Kerchner BS, Lagana S, Aleong RG, Mehdi H, Gutmann R, Weiss R, Dudley SC. AB 16-1: A mutation in the glycerol-3-phosphate dehydrogenase 1-like gene (GPD1L) causes Brugada syndrome. Heart Rhythm 2006;3:S32 (abstract).
Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991;69:1427–1449.
Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nesterenko VV, Burashnikov A, Di Diego JM, Saffitz J, Thomas GP. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999;10:1124–1152.
Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62:116–126.
Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res 1993;72:671–687.
Furukawa T, Myerburg RJ, Furukawa N, Bassett AL, Kimura S. Differences in transient outward currents of feline endocardial and epicardial myocytes. Circ Res 1990;67:1287–1291.
Fedida D, Giles WR. Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J Physiol (Lond) 1991;442:191–209.
Clark RB, Bouchard RA, Salinas-Stefanon E, Sanchez-Chapula J, Giles WR. Heterogeneity of action potential waveforms and potassium currents in rat ventricle. CardiovascRes 1993;27:1795–1799.
Wettwer E, Amos GJ, Posival H, Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res 1994;75:473–482.
Nabauer M, Beuckelmann DJ, Uberfuhr P, Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation 1996;93:168–177.
Di Diego JM, Sun ZQ, Antzelevitch C. I to and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol Heart Circ Physiol 1996;271:H548–H
Volders PG, Sipido KR, Carmeliet E, Spatjens RL, Wellens HJ, Vos MA. Repolarizing K+ currents ITO1 and IKs are larger in right than left canine ventricular midmyocardium. Circulation 1999;99:206–210.
Zicha S, Xiao L, Stafford S, Cha TJ, Han W, Varro A, Nattel S. Transmural expression of transient outward potassium current subunits in normal and failing canine and human hearts. J Physiol 2004;561:735–7
Rosati B, Pan Z, Lypen S, Wang HS, Cohen I, Dixon JE, McKinnon D. Regulation of KChIP2 potassium channel beta subunit gene expression underlies the gradient of transient outward current in canine and human ventricle. J Physiol 2001;533:119–125.
Costantini DL, Arruda EP, Agarwal P, Kim KH, Zhu Y, Zhu W, Lebel M, Cheng CW, Park CY, Pierce SA, Guerchicoff A, Pollevick GD, Chan TY, Kabir MG, Cheng SH, Husain M, Antzelevitch C, Srivastava D, Gross GJ, Hui CC, Backx PH, Bruneau BG. The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 2005;123:347–358.
Takano M, Noma A. Distribution of the isoprenaline-induced chloride current in rabbit heart. Pflugers Arch 1992;420:223–226.
Zygmunt AC. Intracellular calcium activates chloride current in canine ventricular myocytes. Am J Physiol Heart Circ Physiol 1994;267:H1984–H1995.
Cordeiro JM, Greene L, Heilmann C, Antzelevitch D, Antzelevitch C. Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol 2004;286:H 1471–H1479.
Banyasz T, Fulop L, Magyar J, Szentandrassy N, Varro A, Nanasi PP. Endocardial versus epicardial differences in L-type calcium current in canine ventricular myocytes studied by action potential voltage clamp. Cardiovasc Res 2003;58:66–75.
Wang HS, Cohen IS. Calcium channel heterogeneity in canine left ventricular myocytes. J Physiol 2003;547:825–8
Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 1991;68:1729–1741.
Anyukhovsky EP, Sosunov EA, Rosen MR. Regional differences in electrophysiologic properties of epicardium, midmyocardium and endocardium: In vitro and in vivo correlations. Circulation 1996;94:1981–1988.
Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes. Circ Res 1995;76:351–365.
Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001;281:H689–H697.
Zygmunt AC, Goodrow RJ, Antzelevitch C. I(NaCa) contributes to electrical heterogeneity within the canine ventricle. Am J Physiol Heart Circ Physiol 2000;278:H1671–H1678.
Brahmajothi MV, Morales MJ, Reimer KA, Strauss HC. Regional localization of ERG, the channel protein responsible for the rapid component of the delayed rectifier, K+ current in the ferret heart. Circ Res 1997;81:128–135.
Clements SD, Hurst JW. Diagnostic value of ECG abnormalities observed in subjects accidentally exposed to cold. Am J Cardiol 1972;29:729–734.
Thompson R, Rich J, Chmelik F, Nelson WL. Evolutionary changes in the electrocardiogram of severe progressive hypothermia. J Electrocardiol 1977;10:67–
RuDusky BM. The electrocardiogram in hypothermia—the J wave and the Brugada syndrome. Am J Cardiol 2004;93:671–672.
Kraus F. Ueber die wirkung des kalziums auf den kreislauf. Dtsch Med Wochenschr 1920;46:201–203.
Sridharan MR, Horan LG. Electrocardiographic J wave of hypercalcemia. Am J Cardiol 1984;54:672–673.
Antzelevitch C, Sicouri S, Lukas A, Nesterenko VV, Liu DW, Di Diego JM. Regional differences in the electrophysiology of ventricular cells: Physiological and clinical implications. In: Zipes DP, Jalife J, Eds. Cardiac Electrophysiology: From Cell to Bedside, 2nd ed. Philadelphia, PA: W.B. Saunders Co., 1995:228–
Eagle K. Images in clinical medicine. Osborn waves of hypothermia. N Engl J Med 1994;10:680.
Emslie-Smith D, Sladden GE, Stirling GR. The significance of changes in the electrocardiogram in hypothermia. Br Heart J 1959;21:343–351.
Osborn JJ. Experimental hypothermia: Respiratory and blood pH changes in relation to cardiac function. Am J Physiol 1953;175:389–398.
Sridharan MR, Johnson JC, Horan LG, Sohl GS, Flowers NC. Monophasic action potentials in hypercalcemic and hypothermic “J” waves—a comparative study. Am Fed Clin Res 1983;31:219.
Di Diego JM, Antzelevitch C. High [Ca2+]-induced electrical heterogeneity and extrasystolic activity in isolated canine ventricular epicardium: Phase 2 reentry. Circulation 1994;89:1839–1850.
Litovsky SH, Antzelevitch C. Rate dependence of action potential duration and refractoriness in canine ventricular endocardium differs from that of epicardium: Role of the transient outward current. J Am Coll Cardiol 1989;14:1053–1066.
Kilborn MJ, Fedida D. A study of the developmental changes in outward currents of rat ventricular myocytes. J Physiol (Lond) 1990;430:37–60.
Furukawa Y, Akahane K, Ogiwara Y, Chiba S. K+-channel blocking and anti-muscarinic effects of a novel piperazine derivative, INO 2628, on the isolated dog atrium. Eur J Pharm 1991;193:217–222.
Lukas A, Antzelevitch C. Phase 2 reentry as a mechanism of initiation of circus movement reentry in canine epicardium exposed to simulated ischemia. Cardiovasc Res 1996;32:593–603.
Di Diego JM, Antzelevitch C. Pinacidil-induced electrical heterogeneity and extrasystolic activity in canine ventricular tissues. Does activation of ATP-regulated potassium current promote phase 2 reentry? Circulation 1993;88:1177–1189.
Antzelevitch C, Sicouri S, Lukas A, Di Diego JM, Nesterenko VV, Liu DW, Roubache JF, Zygmunt AC, Zhang ZQ, Iodice A. Clinical implications of electrical heterogeneity in the heart: The electrophysiology and pharmacology of epicardial, M, and endocardial cells. In: Podrid PJ, Kowey PR, Eds. Cardiac Arrhythmia: Mechanism, Diagnosis and Management. Baltimore, MD: William & Wilkins, 1995:88–107.
Yan GX, Lankipalli RS, Burke JF, Musco S, Kowey PR. Ventricular repolarization components on the electrocardiogram: Cellular basis and clinical significance. J Am Coll Cardiol 2003;42:401–409.
Aizawa Y, Tamura M, Chinushi M, Naitoh N, Uchiyama H, Kusano Y, Hosono H, Shibata A. Idiopathic ventricular fibrillation and bradycardia-dependent intraventricular block. Am Heart J 1993;126:1473–14
Aizawa Y, Tamura M, Chinushi M, Niwano S, Kusano Y, Naitoh N, Shibata A, Tohjoh T, Ueda Y, Joho K. An attempt at electrical catheter ablation of the arrhythmogenic area in idiopathic ventricular fibrillation. Am Heart J 1992;123:257–260.
Bjerregaard P, Gussak I, Kotar Sl, Gessler JE. Recurrent syncope in a patient with prominent J-wave. Am Heart J 1994;127:1426–1430.
Lukas A, Antzelevitch C. Differences in the electrophysiological response of canine ventricular epicardium and endocardium to ischemia: Role of the transient outward current. Circulation 1993;88:2903–2915.
Thomsen PE, Joergensen RM, Kanters JK, Jensen TJ, Haarbo J, Hagemann A, Vestergaard A, Saermark K. Phase 2 reentry in man. Heart Rhythm 2005;2:797–803.
Antzelevitch C. In vivo human demonstration of phase 2 reentry. Heart Rhythm 2005;2:804–806.
Litovsky SH, Antzelevitch C. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and isoproterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res 1990;67:615–6
Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002;13:698–7
Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999;100:1660–1666.
Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res 1993;72:631–650.
Asano Y, Davidenko JM, Baxter WT, Gray RA, Jalife J. Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. J Am Coll Cardiol 1997;29:831–842.
Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 2004;1:210–217.
Tukkie R, Sogaard P, Vleugels J, De Groot IK, Wilde AA, Tan HL. Delay in right ventricular activation contributes to Brugada syndrome. Circulation 2004;109:1272–1277.
Antzelevitch C, Fish J, Di Diego JM. Cellular mechanisms underlying the Brugada syndrome. In: Antzelevitch C, Brugada P, Brugada J, Brugada R, Eds. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura, 2004:52–77.
Antzelevitch C. The Brugada syndrome: Ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12:268–272.
Antzelevitch C. The Brugada syndrome: Diagnostic criteria and cellular mechanisms. Eur Heart J 2001;22:356–3
Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaitman BR. The Brugada syndrome: Clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 1999;33:5–15.
Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: Current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med 2005;2:408–414.
Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, Perez Riera AR. Brugada syndrome. A decade of progress. Circ Res 2002;91:1114–1119.
Kurita T, Shimizu W, Inagaki M, Suyama K, Taguchi A, Satomi K, Aihara N, Kamakura S, Kobayashi J, Kosakai Y. The electrophysiologic mechanism of ST-segment elevation in Brugada syndrome. J Am Coll Cardiol 2002;40:330–334.
Futterman LG, Lemberg L. Brugada. Am J Crit Care 2001;10:360–364.
Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H, Inoue H. ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: Insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:214–2
Antzelevitch C. Late potentials and the Brugada syndrome. J Am Coll Cardiol 2002;39:1996–1999.
Nagase S, Kusano KF, Morita H, Fujimoto Y, Kakishita M, Nakamura K, Emori T, Matsubara H, Ohe T. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: Using the epicardial lead. J Am Coll Cardiol 2002;39:1992–1995.
Eckardt L, Bruns HJ, Paul M, Kirchhof P, Schulze-Bahr E, Wichter T, Breithardt G, Borggrefe M, Haverkamp W. Body surface area of ST elevation and the presence of late potentials correlate to the inducibility of ventricular tachyarrhythmias in Brugada syndrome. J Cardiovasc Electrophysiol 2002;13:742–749.
Ikeda T, Takami M, Sugi K, Mizusawa Y, Sakurada H, Yoshino H. Noninvasive risk stratification of subjects with a Brugada-type electrocardiogram and no history of cardiac arrest. Ann Noninvasive Electrocardiol 2005;10:396–403.
Shimizu W, Aiba T, Kurita T, Kamakura S. Paradoxic abbreviation of repolarization in epicardium of the right ventricular outflow tract during augmentation of Brugada-type ST segment elevation. J Cardiovasc Electrophysiol 2001;12:1418–1421.
Kandori A, Shimizu W, Yokokawa M, Noda T, Kamakura S, Miyatake K, Murakami M, Miyashita T, Ogata K, Tsukada K. Identifying patterns of spatial current dispersion that characterise and separate the Brugada syndrome and complete right-bundle branch block. Med Biol Eng Comput 2004;42:236–244.
Watanabe H, Chinushi M, Osaki A, Okamura K, Izumi D, Komura S, Hosaka Y, Tanabe Y, Furushima H, Washizuka T, Aizawa Y. Elimination of late potentials by quinidine in a patient with Brugada syndrome. J Electrocardiol 2006;39:63–66.
Marquez MF, Bisteni A, Medrano G, De Micheli A, Guevara M, Iturralde P, Colin L, Hermosillo G, Cardenas M. Dynamic electrocardiographic changes after aborted sudden death in a patient with Brugada syndrome and rate-dependent right bundle branch block. J Electrocardiol 2005;38:256–259.
Nishizaki M, Fujii H, Sakurada H, Kimura A, Hiraoka M. Spontaneous T wave alternans in a patient with Brugada syndrome—responses to intravenous administration of class I antiarrhythmic drug, glucose tolerance test, and atrial pacing. J Cardiovasc Electrophysiol 2005;16:217–220.
Tada H, Nogami A, Shimizu W, Naito S, Nakatsugawa M, Oshima S, Taniguchi K. ST segment and T wave alternans in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2000;23:413–415.
Chinushi M, Washizuka T, Okumura H, Aizawa Y. Intravenous administration of class I antiarrhythmic drugs induced T wave alternans in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:493–495.
Chinushi Y, Chinushi M, Toida T, Aizawa Y. Class I antiarrhythmic drug and coronary vasospasminduced T wave alternans and ventricular tachyarrhythmia in a patient with Brugada syndrome and vasospastic angina. J Cardiovasc Electrophysiol 2002;13:191–194.
Takagi M, Doi A, Takeuchi K, Yoshikawa J. Pilsicanide-induced marked T wave alternans and ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002;13: 837.
Ohkubo K, Watanabe I, Okumura Y, Yamada T, Masaki R, Kofune T, Oshikawa N, Kasamaki Y, Saito S, Ozawa Y, Kanmatsuse K. Intravenous administration of class I antiarrhythmic drug induced T wave alternans in an asymptomatic Brugada syndrome patient. Pacing Clin Electrophysiol 2003;26:1900–1903.
Morita H, Morita ST, Nagase S, Banba K, Nishii N, Tani Y, Watanabe A, Nakamura K, Kusano KF, Emori T, Matsubara H, Hina K, Kita T, Ohe T. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003;42:1624–1631.
Morita H, Nagase S, Kusano K, Ohe T. Spontaneous T wave alternans and premature ventricular contractions during febrile illness in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002;13:816–818.
Morita H, Zipes DP, Lopshire J, Morita ST, Wu J. T wave alternans in an in vitro canine tissue model of Brugada syndrome. Am J Physiol Heart Circ Physiol 2006;291:H421–H428.
Babaliaros VC, Hurst JW. Tricyclic antidepressants and the Brugada syndrome: An example of Brugada waves appearing after the administration of desipramine. Clin Cardiol 2002;25:395–398.
Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002;346:1591–1592.
Tada H, Sticherling C, Oral H, Morady F. Brugada syndrome mimicked by tricyclic antidepressant overdose. J Cardiovasc Electrophysiol 2001;12: 275.
Pastor A, Nunez A, Can tale C, Cosio FG. Asymptomatic Brugada syndrome case unmasked during dimenhydrinate infusion. J Cardiovasc Electrophysiol 2001;12:1192–1194.
Ortega-Carnicer J, Bertos-Polo J, Gutierrez-Tirado C. Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion. J Electrocardiol 2001;34: 345–349.
Nogami A, Nakao M, Kubota S, Sugiyasu A, Doi H, Yokoyama K, Yumoto K, Tamaki T, Kato K, Hosokawa N, Sagai H, Nakamura H, Nitta J, Yamauchi Y, Aonuma K. Enhancement of J-ST-segment elevation by the glucose and insulin test in Brugada syndrome. Pacing Clin Electrophysiol 2003;26:332–337.
Araki T, Konno T, Itoh H, Ino H, Shimizu M. Brugada syndrome with ventricular tachycardia and fibrillation related to hypokalemia. Circ J 2003;67:93–95.
Akhtar M, Goldschlager NF. Brugada electrocardiographic pattern due to tricyclic antidepressant overdose. J Electrocardiol 2006;39:336–339.
Darbar D, Yang T, Churchwell K, Wilde AA, Roden DM. Unmasking of Brugada syndrome by lithium. Circulation 2005;112:1527–1531.
Noda T, Shimizu W, Taguchi A, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S. ST-segment elevation and ventricular fibrillation without coronary spasm by intracoronary injection of acetylcholine and/or ergonovine maleate in patients with Brugada syndrome. J Am Coll Cardiol 2002; 40:1841–1847.
Chinushi M, Furushima H, Tanabe Y, Washizuka T, Aizawaz Y. Similarities between Brugada syndrome and ischemia-induced ST-segment elevation. Clinical correlation and synergy. J Electrocardiol 2005;38(Suppl.):18–21.
Nimmannit S, Malasit P, Chaovakul V, Susaengrat W, Vasuvattakul S, Nilwarangkur S. Pathogenesis of sudden unexplained nocturnal death (lai tai) and endemic distal renal tubular acidosis. Lancet 1991;338:930–932.
Proclemer A, Facchin D, Feruglio GA, Nucifora R. Recurrent ventricular fibrillation, right bundlebranch block and persistent ST segment elevation in V1-V3: A new arrhythmia syndrome? A clinical case report (see comments). G Ital Cardiol 1993; 23:1211–1218.
Mizumaki K, Fujiki A, Tsuneda T, Sakabe M, Nishida K, Sugao M, Inoue H. Vagal activity modulates spontaneous augmentation of ST elevation in daily life of patients with Brugada syndrome. J Cardiovasc Electrophysiol 2004;15:667–673.
Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, Haverkamp W, Borggrefe M, Schober O, Breithardt G, Schafers M. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702–706.
Ikeda T, Abe A, Yusa S, Nakamura K, Ishiguro H, Mera H, Yotsukura M, Yoshino H. The full stomach test as a novel diagnostic technique for identifying patients at risk for Brugada syndrome. J Cardiovasc Electrophysiol 2006;17:602–607.
Gonzalez Rebollo G, Madrid H, Carcia A, Garcia de Casto A, Moro AM. Reccurrent ventricular fibrillation during a febrile illness in a patient with the Brugada syndrome. Rev Esp Cardiol 2000;53: 755–757.
Madle A, Kratochvil Z, Polivkova A. [The Brugada syndrome]. Vnitr Lek 2002;48:255–258.
Kum L, Fung JWH, Chan WWL, Chan GK, Chan YS, Sanderson JE. Brugada syndrome unmasked by febrile illness. Pacing Clin Electrophysiol 2002;25:1660–1661.
Keller DI, Huang H, Zhao J, Frank R, Suarez V, Delacretaz E, Brink M, Osswald S, Schwick N, Chahine M. A novel SCN5A mutation, F1344S, identified in a patient with Brugada syndrome and fever-induced ventricular fibrillation. Cardiovasc Res 2006;70:521–529.
Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, Scornik FS, Antzelevitch C. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106:2004–2011.
Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 2000;33(Suppl.):41–47.
Brugada P, Brugada R, Brugada J, Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 1999;83:98D–100D.
Haissaguerre M, Extramiana F, Hocini M, Cauchemez B, Jais P, Cabrera JA, Farre G, Leenhardt A, Sanders P, Scavee C, Hsu LF, Weerasooriya R, Shah DC, Frank R, Maury P, Delay M, Garrigue S, Clementy J. Mapping and ablation of ventricular fibrillation associated with long-QT and Brugada syndromes. Circulation 2003;108:925–928.
Kron J, Herre J, Renfroe EG, Rizo-Patron C, Raitt M, Halperin B, Gold M, Goldner B, Wathen M, Wilkoff B, Olarte A, Yao Q. Lead-and devicerelated complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001;141:92–98.
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337:1576–1583.
Belhassen B, Viskin S, Antzelevitch C. The Brugada syndrome: Is an implantable cardioverter defibrillator the only therapeutic option? Pacing Clin Electrophysiol 2002;25:1634–1640.
Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. In: Kass R, Clancy CE, Eds. Handbook of Experimental Pharmacology. New York: Springer-Verlag, 2006:305–330.
Chinushi M, Aizawa Y, Ogawa Y, Shiba M, Takahashi K. Discrepant drug action of disopyramide on ECG abnormalities and induction of ventricular arrhythmias in a patient with Brugada syndrome. J Electrocardiol 1997;30:133–136.
Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin JA. Clinical Approaches to Tachy arrhythmias. The Brugada Syndrome. Armonk, NY: Futura Publishing Company, Inc., 1999.
Grant AO. Electrophysiological basis and genetics of Brugada syndrome. J Cardiovasc Electrophysiol 2005;16(Suppl. 1):S3–S7.
Alings M, Dekker L, Sadee A, Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1420–1422.
Belhassen B, Viskin S. Pharmacologic approach to therapy of Brugada syndrome: Quinidine as an alternative to ICD therapy? In: Antzelevitch C, Brugada P, Brugada J, Brugada R, Eds. The Brugada Syndrome: From Bench to Bedside. Oxford, UK: Blackwell Futura, 2004:202–211.
Marquez MF, Rivera J, Hermosillo AG, Iturralde P, Colin L, Moragrega JL, Cardenas M. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 2005;28:870–873.
Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999;10: 1301–1312.
Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, Guicheney P, Di Fusco S, Rey JL, Cauchemez B, Leenhardt A. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004;43:1853–1860.
Mok NS, Chan NY, Chi-Suen CA. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 2004;27:821–823.
Marquez MF, Rivera J, Hermosillo AG, Iturralde P, Colin L, Moragrega JL, Cardenas M. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 2005;28:870–873.
Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: Low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 2006;47: 359–364.
Fish JM, Extramiana F, Antzelevitch C. Tedisamil abolishes the arrhythmogenic substrate responsible for VT/VF in an experimental model of the Brugada syndrome. Heart Rhythm 2004;1(1S): S158 (abstract).
Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine (Baltimore) 2003;82:282–290.
Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 2002;17:43–51.
Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003;24:619–625.
Fish JM, Extramiana F, Antzelevitch C. AVE0118, an I to and I Kur blocker, suppresses VT/VF in an experimental model of the Brugada syndrome. Circulation 2004;110(17):III–193 (abstract).
Suzuki H, Torigoe K, Numata O, Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000;11:1277–1280.
Tanaka H, Kinoshita O, Uchikawa S, Kasai H, Nakamura M, Izawa A, Yokoseki O, Kitabayashi H, Takahashi W, Yazaki Y, Watanabe N, Imamura H, Kubo K. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 2001;24:1293–1294.
Haghjoo M, Arya A, Heidari A, Sadr-Ameli MA. Suppression of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:674.
Fish JM, Welchons DR, Kim YS, Lee SH, Ho WK, Antzelevitch C. Dimethyl lithospermate B, an extract of danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation 2006;113:1393–1400.
Nademanee K, Veerakul G, Schwab M. Predisposing factors in the Brugada syndrome. In: Antzelevitch C, Brugada P, Eds. Brugada Syndrome. Elmsford, UK: Blackwell Publishing, 2004: 157–165.
Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol 1998;9:1167–1172.
Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S. Flecainide test in Brugada syndrome: A reproducible but risky tool. Pacing Clin Electrophysiol 2003;26:338–341.
Takenaka S, Emori T, Koyama S, Morita H, Fukushima K, Ohe T. Asymptomatic form of Brugada syndrome. Pacing Clin Electrophysiol 1999;22:1261–1263.
Matana A, Goldner V, Stanic K, Mavric Z, Zaputovic L, Matana Z. Unmasking effect of pro-pafenone on the concealed form of the Brugada phenomenon. Pacing Clin Electrophysiol 2000;23: 416–418.
Rolf S, Bruns HJ, Wichter T, Kirchhof P, Ribbing M, Wasmer K, Paul M, Breithardt G, Haverkamp W, Eckardt L. The ajmaline challenge in Brugada syndrome: Diagnostic impact, safety, and recommended protocol. Eur Heart J 2003;24:1104–1112.
Sarkozy A, Caenepeel A, Geelen P, Peytchev P, de Zutter M., Brugada P. Cibenzoline induced Brugada ECG pattern. Europace 2005;7:537–539.
Aouate P, Clerc J, Viard P, Seoud J. Propranolol intoxication revealing a Brugada syndrome. J Cardiovasc Electrophysiol 2005;16:348–351.
Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998;9:508–512.
Bigwood B, Galler D, Amir N, Smith W. Brugada syndrome following tricyclic antidepressant overdose. Anaesth Intensive Care 2005;33:266–270.
Bolognesi R, Tsialtas D, Vasini P, Conti M, Manca C. Abnormal ventricular repolarization mimicking myocardial infarction after heterocyclic antidepressant overdose. Am J Cardiol 1997;79:242–245.
Rouleau F, Asfar P, Boulet S, Dube L, Dupuis JM, Alquier P, Victor J. Transient ST segment elevation in right precordial leads induced by psychotropic drugs: Relationship to the Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:61–65.
Lopez-Barbeito B, Lluis M, Delgado V, Jimenez S, az-Infante E, Nogue-Xarau S, Brugada J. Diphenhydramine overdose and Brugada sign. Pacing Clin Electrophysiol 2005;28:730–732.
Littmann L, Monroe MH, Svenson RH. Brugada-type electrocardiographic pattern induced by cocaine. Mayo Clin Proc 2000;75:845–849.
Shimizu W. Acquired forms of the Brugada syndrome. J Electrocardiol 2005;38(Suppl.):22–25.
van Den Berg MP, Wilde AA, Viersma TJW, Brouwer J, Haaksma J, van der Hout AH, Stolte-Dijkstra I, Bezzina TCR, Van Langen IM, Beaufort-Krol GC, Cornel JH, Crijns HJ. Possible bradycardic mode of death and successful pacemaker treatment in a large family with features of long QT syndrome type 3 and Brugada syndrome. J Cardiovasc Electrophysiol 2001;12:630–636.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag London Limited
About this chapter
Cite this chapter
Antzelevitch, C., Viskin, S. (2008). Brugada Syndrome: Cellular Mechanisms and Approaches to Therapy. In: Gussak, I., Antzelevitch, C., Wilde, A.A.M., Friedman, P.A., Ackerman, M.J., Shen, WK. (eds) Electrical Diseases of the Heart. Springer, London. https://doi.org/10.1007/978-1-84628-854-8_35
Download citation
DOI: https://doi.org/10.1007/978-1-84628-854-8_35
Publisher Name: Springer, London
Print ISBN: 978-1-84628-853-1
Online ISBN: 978-1-84628-854-8
eBook Packages: MedicineMedicine (R0)